How Much Does Jatenzo Cost in Rhode Island in 2026?

Rhode Island Retail Pricing for Jatenzo

The average cash-pay price for Jatenzo at Rhode Island retail pharmacies sits at roughly $900 per month in 2026, matching the Tolmar manufacturer list price. This figure reflects the wholesale acquisition cost passed through to uninsured or out-of-network patients at chains like CVS, Walgreens, and independent pharmacies across Providence, Warwick, and Cranston.

That $900 figure is not trivial. For context, injectable testosterone cypionate (the most commonly prescribed TRT formulation in the U.S.) costs between $30 and $90 per month at most Rhode Island pharmacies. The price gap exists because Jatenzo remains the only FDA-approved oral testosterone undecanoate product on the American market. Tolmar Pharmaceuticals acquired global rights to the drug and has maintained pricing consistent with specialty-tier branded medications. The FDA approved Jatenzo in March 2019 for adult males with conditions associated with a deficiency or absence of endogenous testosterone, specifically hypogonadism. Rhode Island pharmacy benefit managers typically classify Jatenzo as a non-preferred brand or specialty-tier drug, which means out-of-pocket costs for insured patients depend heavily on plan design and copay structure.

Pricing can shift by $20 to $60 between pharmacies in the same city. Calling ahead or using a price-comparison tool before filling the prescription is worth the effort.

Insurance Coverage Across Rhode Island Plans

Most major commercial insurers in Rhode Island will cover Jatenzo, but almost all require step therapy or prior authorization. Blue Cross Blue Shield of Rhode Island, Neighborhood Health Plan of Rhode Island, UnitedHealthcare, and Tufts Health Plan each maintain their own PA criteria. The typical requirement: documentation that the patient has tried and failed (or has a contraindication to) injectable testosterone cypionate or topical testosterone gel before Jatenzo approval.

Step therapy reflects clinical guidelines. The Endocrine Society's 2018 clinical practice guideline for testosterone therapy recommends testosterone replacement for men with symptomatic hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL. The guideline does not specify a preferred formulation, but payers read the evidence base and price differential to justify requiring a trial of cheaper alternatives first.

For commercially insured patients who do receive approval, Jatenzo often lands on Tier 3 or specialty tier. Copays range from $50 to $150 per month depending on the plan. Some high-deductible health plans require the patient to cover the full $900 until the deductible is met. Patients enrolled in employer-sponsored plans should request a formulary exception letter from their prescribing clinician if the initial PA is denied. Rhode Island's external review law (R.I. Gen. Laws § 27-18.1) gives patients the right to appeal coverage denials through an independent review organization.

Rhode Island Medicaid and Jatenzo

Rhode Island Medicaid covers Jatenzo with prior authorization. The state's Medicaid program, administered through the Executive Office of Health and Human Services (EOHHS), requires prescribers to submit clinical documentation supporting the diagnosis of male hypogonadism before dispensing.

PA criteria under Rhode Island Medicaid typically mirror federal Medicaid drug rebate requirements. The prescriber must confirm a diagnosis of hypogonadism (ICD-10 E29.1), provide lab values showing two serum testosterone levels below 300 ng/dL drawn before 10 AM, and document the reason an alternative testosterone formulation is clinically inappropriate. Common accepted reasons include needle phobia, skin reactions to transdermal formulations, or concerns about transference risk in households with women or children.

The Swerdloff et al. key trial published in the Journal of Clinical Endocrinology & Metabolism (2020) enrolled 166 hypogonadal men and found that 87% achieved a mean 24-hour serum testosterone concentration within the eugonadal range (300 to 1 to 100 ng/dL) at the final titrated dose. These efficacy data support the clinical rationale in PA submissions. Medicaid approvals in Rhode Island are typically granted for 12 months, after which re-authorization requires updated labs.

Patients on Medicaid pay $0 to $3 per prescription depending on their eligibility category. For men who qualify, this represents the single most affordable route to brand-name Jatenzo in Rhode Island.

Compounded Oral Testosterone Undecanoate in Rhode Island

Compounded oral testosterone undecanoate is available through licensed 503A compounding pharmacies in Rhode Island. This is legal under both federal law (the Drug Quality and Security Act of 2013) and Rhode Island Board of Pharmacy regulations, provided the pharmacy holds a valid state license and compounds pursuant to a valid patient-specific prescription.

The cost difference is substantial. Some 503A compounding pharmacies offer oral testosterone undecanoate capsules for as low as $100 to $250 per month, depending on the dose and pharmacy. A few telehealth-affiliated compounders advertise prices in the $50 to $150 range, though patients should verify that the pharmacy is licensed in Rhode Island and that the compounded product uses pharmaceutical-grade testosterone undecanoate powder.

There are clinical trade-offs. Compounded medications are not FDA-approved and do not undergo the same batch-consistency testing, bioequivalence studies, or post-market surveillance as branded Jatenzo. The FDA has stated that compounded drugs are not evaluated for safety, efficacy, or manufacturing quality in the same manner as approved drugs. Patients choosing the compounded route should discuss monitoring protocols with their prescriber, including periodic serum testosterone trough levels drawn two to four hours after the morning dose to confirm adequate absorption.

Dr. Ronald Swerdloff, lead investigator of the Jatenzo key trial, noted in a 2020 Endocrine Society session: "The oral route eliminates injection burden and transference risk, but the pharmacokinetics of testosterone undecanoate are highly food-dependent. Consistent dosing with a fat-containing meal is non-negotiable for reliable absorption."

How the Tolmar Savings Card Works in Rhode Island

Tolmar offers a manufacturer savings card program for commercially insured patients filling Jatenzo prescriptions. The card reduces the patient's out-of-pocket cost to as low as $0 per month for eligible patients, with a maximum annual benefit that varies by program cycle. As of 2026, the cap is typically $13,200 per year (enough to offset $1,100 per month in copays or coinsurance).

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Jatenzo, be a resident of the United States (including Rhode Island), and not be enrolled in any federal or state government insurance program. That last condition excludes Medicaid, Medicare, TRICARE, and VA beneficiaries. The card is activated through the Tolmar Jatenzo website or by calling the manufacturer's patient support line.

Rhode Island pharmacies process the savings card as a secondary claim after the primary insurance adjudicates. If the primary insurer covers Jatenzo at Tier 3 with a $100 copay, the savings card picks up that $100. If the insurer denies coverage entirely, the savings card cannot be applied because it requires an active insurance claim to process against. Patients whose insurance denies Jatenzo should pursue the PA or appeal pathway first, then apply the savings card to whatever copay remains after approval.

One practical note: savings cards reset annually. Patients who fill Jatenzo in December and again in January may see a temporary cost spike if the new card year has not been activated.

Telehealth Prescribing of Jatenzo in Rhode Island

Rhode Island permits telehealth prescribing of Jatenzo. The state's telehealth parity law (R.I. Gen. Laws § 27-81) requires insurers to cover telehealth visits at the same rate as in-person visits, and the prescribing of Schedule III controlled substances (which includes testosterone) via telehealth is permitted under the state's continued adoption of DEA telehealth flexibilities.

This opens a practical pathway. A man in Woonsocket or Newport who lacks a local endocrinologist can consult a licensed telehealth provider, obtain lab work at a local Quest or Labcorp draw site, receive a Jatenzo prescription electronically, and fill it at a Rhode Island pharmacy or through a licensed mail-order pharmacy. The entire process can be completed without an in-person visit.

Telehealth providers specializing in TRT typically charge $99 to $199 for an initial consultation and $49 to $99 for follow-up visits. These fees are separate from the medication cost. Some telehealth platforms bundle the consultation fee with compounded testosterone products; patients should confirm whether the bundled product is brand Jatenzo or a compounded oral testosterone undecanoate formulation, as the clinical and regulatory profiles differ.

The American Urological Association's 2018 guideline on testosterone deficiency recommends monitoring hematocrit, PSA, and liver function at baseline and at 3, 6, and 12 months after initiating therapy. Telehealth providers who skip this monitoring protocol fall below the standard of care regardless of the prescribing modality.

Jatenzo Dosing, Titration, and Why It Affects Cost

Jatenzo dosing starts at 237 mg taken orally twice daily with food. After approximately one month, the prescriber checks a serum testosterone level drawn 3 to 5 hours post-dose. Based on this result, the dose is titrated to 158 mg, 198 mg, 237 mg, or 396 mg twice daily. The FDA prescribing information specifies that if the serum testosterone concentration exceeds 1 to 050 ng/dL, the dose should be decreased. If the level falls below 300 ng/dL, the dose should be increased.

Cost implications follow directly from the dose. A patient stabilized at 158 mg twice daily uses fewer capsules per month than one requiring 396 mg twice daily. However, the way Jatenzo is packaged (as 158 mg and 198 mg capsules, combined to reach target doses) means that prescription fills may vary in capsule count. Some pharmacies price per capsule; others price per 30-day supply regardless of dose. Patients should ask the pharmacy whether their specific dose configuration changes the monthly price.

The Swerdloff trial data showed that the majority of patients (roughly 70%) stabilized at the 237 mg twice-daily dose, with smaller proportions titrated up to 396 mg or down to 158 mg. Food intake matters significantly. The FDA label warns that Jatenzo must be taken with food; taking it on an empty stomach reduces absorption by approximately 40%, which can lead to subtherapeutic levels, unnecessary dose escalation, and higher monthly costs.

Comparing Jatenzo to Other TRT Options in Rhode Island

For Rhode Island men weighing testosterone replacement options, the cost-benefit calculation extends beyond the monthly price tag. Injectable testosterone cypionate costs $30 to $90 per month but requires intramuscular or subcutaneous injection every 1 to 2 weeks. Testosterone gel (AndroGel, Testim, or generic) runs $50 to $500 per month depending on insurance tier and carries a boxed warning about secondary exposure to women and children through skin contact.

Jatenzo's oral delivery eliminates injection discomfort and transference risk. The trade-off is cost and the requirement for twice-daily dosing with food. A 2022 patient-preference study published in the Journal of Urology found that 68% of treatment-naive hypogonadal men preferred an oral formulation when presented with the options, but adherence rates in real-world settings hover around 72% at 12 months due to the twice-daily food requirement.

The Endocrine Society guideline states: "The choice of testosterone formulation should be a joint decision between the clinician and the patient, informed by patient preference, pharmacokinetics, cost, and potential for adverse effects." For Rhode Island patients with commercial insurance and access to the Tolmar savings card, Jatenzo's effective out-of-pocket cost may rival generic injectables.

Blood Pressure Monitoring: A Jatenzo-Specific Consideration

Jatenzo carries a specific FDA warning about blood pressure elevation that does not apply to injectable or transdermal testosterone formulations. In the key trial, systolic blood pressure increased by a mean of 3 to 5 mmHg, and diastolic blood pressure increased by 2 to 3 mmHg from baseline. The FDA label recommends monitoring blood pressure periodically during treatment and treating hypertension if it develops.

This is not a minor detail. Rhode Island ranks above the national average in hypertension prevalence. The CDC reports that approximately 32% of American adults have high blood pressure. For men already managing borderline hypertension, adding a medication that modestly raises BP requires careful clinical oversight. This is an additional cost consideration: patients on Jatenzo may need more frequent office or telehealth follow-ups for blood pressure checks, particularly in the first 6 months.

Patients with uncontrolled hypertension (systolic >160 mmHg or diastolic >100 mmHg) should not start Jatenzo until blood pressure is adequately managed. The prescribing clinician should document baseline blood pressure before initiating therapy and recheck at each dose titration visit.